Good News for ITP Patients: Ianalumab + Eltrombopag Prolongs Time to Treatment Failure VS Eltrombopag Alone
Roger Schutgens, Professor of Thrombosis and Haemostasis at UMC Utrecht, shared on LinkedIn:
“Good news for patients with ITP.
Recently, the results of the VAYHIT2 trial have been published in The New England Journal of Medicine, showing that a course of B-cell–targeted therapy (ianalumab) combined with eltrombopag significantly prolongs time to treatment failure compared to eltrombopag alone in adults with immune thrombocytopenia after first-line steroids (13 months versus 4.7 months).
More patients were able to taper and discontinue eltrombopag (62% versus 39%), supporting the concept of early, disease-modifying treatment in ITP.
It was a joyfull ride to be part of this endeavor.”
Title: Ianalumab plus Eltrombopag in Immune Thrombocytopenia
Authors: Adam Cuker, Thomas Stauch, Nichola Cooper et al.
Read the full article.
Hemostasis Today has more posts you may find interesting.
-
May 22, 2026, 10:23Rucha Patil: Insights from The National Haemophilia Conclave 2026
-
May 22, 2026, 10:11Narat Srivali: New Systematic Review and Meta-Analysis on Glucocorticoid Therapy and The Risk of VTE
-
May 22, 2026, 10:02Greta Mulders: Nursing Leadership in Haemophilia Gene Therapy
-
May 22, 2026, 08:45Dirk Sibbing: Ethnicity and Antiplatelet Therapy Outcomes in CCS
-
May 22, 2026, 08:35Jason Brandon: On Lyophilized Hemostatic Supplementation at Simmons Research Day 2026
-
May 22, 2026, 08:28Inconsistent D-Dimer Assay Reporting in VTE Studies – JTH
-
May 22, 2026, 08:21Vincent Jongkind: We Invite You to Participate in a Delphi Study for a Core Outcome Set in Acute Limb Ischemia
-
May 22, 2026, 07:46Jae Hyun Byun: Spatial Transcriptomics and the Emerging Complexity of Plaque Vulnerability
-
May 22, 2026, 07:45Thom Lysen: Tracking TTS Risk After COVID-19 Viral Vector-Based Vaccines